Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients

Hotta, Kikuko; Funahashi, Tohru; Arita, Yukio; Takahashi, Masahiko; Matsuda, Morihiro; Okamoto, Yoshihisa; Iwahashi, Hiromi; Kuriyama, Hiroshi; Ouchi, Noriyuki; Maeda, Kazuhisa; Nishida, Makoto; Kihara, Shinji; Sakai, Naohiko; Nakajima, Tadahisa; Hasegawa, K.; Muraguchi, Masahiro; Ohmoto, Yasukazu; Nakamura, Tadashi; Yamashita, Shizuya; Hanafusa, Toshiaki; Matsuzawa, Yūji

doi:10.1161/01.atv.20.6.1595

Cited by 2,824 publications

(2,381 citation statements)

References 25 publications

Supporting

163

Mentioning

2,099

Contrasting

Unclassified

Order By: Relevance

“…In the present study, we observed a significant decrease of the plasma adiponectin level in patients with type 2 diabetes, and this finding agrees with the report of Hotta et al 19 Abnormalities of lipid metabolism and haemostatic factors, as well as the presence of insulin resistance, are thought to contribute to atherosclerotic vascular damage in diabetes. Insulin resistance induces hyperinsulinaemia and alters the secretion by adipose tissue of various proteins that are regulated by insulin.…”

Section: Discussionsupporting

confidence: 94%

“…[12][13][14][15][16] Adiponectin is the most abundant fat-specific hormone, being exclusively expressed by and secreted from adipose tissue. 17 The plasma adiponectin concentration is decreased in obese individuals 17,18 and patients with type 2 diabetes, 19 and its level is closely related to whole-body insulin sensitivity. 20 This protein is abundant in the circulation 18 and suppresses attachment of monocytes to endothelial cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

Nifedipine, a dihydropyridine calcium antagonist, improves endothelial function in patients with hypercholesterolaemia by enhancing nitric oxide (NO) activity, and increases endothelial NO bioavailability by antioxidant mechanisms. We administered a long-acting nifedipine formulation (controlled release (CR) nifedipine: 20 mg/day) to hypertensive patients for 6 months. There were no other changes of drug treatment during therapy with CR nifedipine. Clinical and biochemical data obtained before and after CR nifedipine administration were compared. All markers were measured by enzyme-linked immunosorbant assay. The levels of soluble markers (soluble CD40 ligand, soluble P-selectin, and soluble E-selectin), microparticles (MP) (platelet-derived MP, monocyte-derived MP, and endothelial cell-derived MP), and adiponectin differed between the control group and the hypertension group. The levels of these markers were also different in hypertensive patients with and without type 2 diabetes compared with the control group. In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment. In contrast, markers were unchanged in the hypertensive patients without type 2 diabetes. Adiponectin was increased after 6 months of CR nifedipine treatment in hypertensive patients with type 2 diabetes. The effects of CR nifedipine on platelet/monocyte activation and adiponectin levels demonstrated in the present study indicate the potential effectiveness of calcium antagonist therapy for hypertensive patients with type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

show abstract

“…A number of previous articles have demonstrated the strong inverse relationship between obesity and adiponectin as well as between diabetes and adiponectin. [34][35][36][37][38] However, in most cases, the diabetic groups had increased BMI, and the effects of obesity vs diabetic status have not been directly addressed. For example, a recent study in 73 type 2 diabetic Japanese subjects demonstrated decreased adiponectin in diabetic subjects.…”

Section: Discussionmentioning

confidence: 99%

Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes

et al. 2005

View full text Add to dashboard Cite

Objective: The purpose of this study was to determine the relationships between adipocyte hormones acylation stimulating protein (ASP), adiponectin, complement C3 (C3) (ASP precursor) and insulin, C-reactive protein (CRP), lipid profiles and insulin resistance in lean vs obese type 2 diabetes subjects. Subjects: Lean type 2 diabetes subjects (DL n ¼ 27) vs obese type 2 diabetes subjects (DO n ¼ 55) were compared to agematched nondiabetic groups (Obese, OB n ¼ 55 and control, CTL n ¼ 50).Results: The DO group demonstrated significant increases in plasma ASP and C3 with decreases in plasma adiponectin as compared to CTL. Interestingly, these increases in ASP and C3 were as high, or greater, in the DL group in spite of normal weight. By contrast adiponectin in the DL group was comparable to CTL, in spite of marked insulin resistance. C3 correlated with insulin, glucose and homeostasis model assessment of insulin resistance (HOMA-IR); ASP correlated with body mass index (BMI), glucose, insulin and plasma lipid parameters (non-esterified fatty acids (NEFA), triglyceride, cholesterol and apolipoprotein B). Adiponectin correlated with BMI, glucose, NEFA, triglyceride, high-density lipoprotein cholesterol and apolipoprotein A1 but not HOMA-IR, ASP or C3. CRP correlated only with HOMA-IR. Conclusion: Increased ASP and C3 are both associated with diabetes and related lipid factors but are not regulated coordinately. Adiponectin appears to be more closely related to body size (decreased in obese subjects) than insulin resistance in these subjects.

show abstract

“…Adiponectin plasma levels have been shown to be reduced, particularly in obese, 7 insulin-resistant patients 8 and in type 2 diabetics. 9 From three distinct multimeric complexes identified in human plasma, high (HMW), medium (MMW) and low (LMW) molecular weight, only the HMW adiponectin plasma levels are positively associated with insulin sensitivity. 10 To verify a hypothesis that PCB 153 may modify secretory functions of adipose tissue in obese women, plasma levels of PCB 153, adiponectin and other inflammatory markers were measured in a small cohort of obese patients before and after a weight-reducing regimen, which was based on a low-calorie-diet intervention.…”

Section: Introductionmentioning

confidence: 99%

Negative association between plasma levels of adiponectin and polychlorinated biphenyl 153 in obese women under non-energy-restrictive regime

et al. 2008

View full text Add to dashboard Cite

The aim of this study was to reveal whether accumulation of the persistent organic pollutants (POPs), especially polychlorinated biphenyl (2,2 0 ,4,4 0 ,5,5 0 -hexachlorobiphenyl, PCB 153), affects plasma levels of adiponectin in obese patients. The study was designed as a longitudinal intervention trial with a control group, where 27 obese women (body mass index (BMI)430 kg/m 2 ; age 21-74 years) were studied before (OB) and after (OB-LCD) a 3-month low-calorie-diet intervention (LCD; 5 MJ daily). As the control group, 9 female volunteers without LCD intervention were used (C; BMI ¼ 19-25 kg/m 2 ; age 21-64 years). Plasma levels of PCB 153 were measured by high-resolution gas chromatography with electron capture detection; total adiponectin and insulin plasma levels were quantified by immunoassays; and adiponectin multimeric complexes were quantified by immunoblotting. Plasma levels of total adiponectin, high and medium molecular weight multimers significantly negatively correlated with plasma levels of PCB 153 in OB, but not in C or in OB-LCD, whereas the LCD intervention lowered BMI by 3.3±3.0 kg/m 2 . Our results may suggest suppression of adiponectin by PCB 153 in obese women under non-energy-restrictive regime, which may contribute to the known association of PCB 153 and other POPs with type 2 diabetes.

show abstract

Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients

Cited by 2,824 publications

References 25 publications

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes

Negative association between plasma levels of adiponectin and polychlorinated biphenyl 153 in obese women under non-energy-restrictive regime

Contact Info

Product

Resources

About